Neoadjuvant Her2 therapy for Breast Cancer

Sarmen Sarkissian, MD

The holy grail of neoadjuvant treatment approaches for breast cancer has been the achievement of pathologic complete remission rates (pCR) and improvements in overall survival. This has been achieved with chemotherapy, but there is now emerging data with a variety of different Anti-Her2 agents. The overall survival has not always correlated well with pCR rates. In this study, the authors conclude that patients that achieve pCR after treatment with an oral an intravenous form of Her2 blockade can have statistically significant improvements in overall survival.

http://ascopubs.org/doi/full/10.1200/JCO.2017.75.9175

---